Cypress Capital Group Sells 2,521 Shares of Solventum Co. (NYSE:SOLV)

Cypress Capital Group decreased its stake in shares of Solventum Co. (NYSE:SOLV) by 12.2% during the 4th quarter, Holdings Channel reports. The firm owned 18,185 shares of the company’s stock after selling 2,521 shares during the period. Cypress Capital Group’s holdings in Solventum were worth $1,201,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Modus Advisors LLC acquired a new position in shares of Solventum during the 4th quarter worth approximately $25,000. Stonebridge Financial Group LLC acquired a new position in Solventum in the 4th quarter valued at $26,000. True Wealth Design LLC grew its holdings in Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new position in Solventum in the 4th quarter valued at $32,000. Finally, Prospera Private Wealth LLC bought a new stake in shares of Solventum during the 3rd quarter valued at $35,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on SOLV shares. Wells Fargo & Company upped their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. The Goldman Sachs Group increased their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday. Piper Sandler increased their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Finally, Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus price target of $78.86.

Solventum Stock Down 1.5 %

Shares of NYSE:SOLV opened at $78.95 on Wednesday. The business’s 50 day simple moving average is $73.02 and its two-hundred day simple moving average is $70.33. The firm has a market cap of $13.64 billion and a P/E ratio of 28.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.